1. Apoptosis Immunology/Inflammation
  2. Apoptosis SOD Caspase Bcl-2 Family
  3. Pendimethalin

Pendimethalin  (Synonyms: 二甲戊灵)

目录号: HY-B0862 纯度: 99.75%
COA 产品使用指南

Pendimethalin 是具有口服活性的除草剂,可控制一年生禾草和某些阔叶杂草。Pendimethalin 通过激活内质网应激介导的线粒体功能障碍,诱导人脐静脉内皮细胞的凋亡 (Apoptotic) 细胞死亡。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Pendimethalin Chemical Structure

Pendimethalin Chemical Structure

CAS No. : 40487-42-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ¥385
In-stock
100 mg ¥350
In-stock
500 mg ¥550
In-stock
1 g ¥880
In-stock
5 g ¥2200
In-stock
10 g ¥3300
In-stock
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Pendimethalin:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Pendimethalin is an orally active herbicide that controls annual grasses and certain broadleaf weeds. Pendimethalin induces Apoptotic cell death through activating ER stress-mediated mitochondrial dysfunction in human umbilical vein endothelial cells[1][2][3][4].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
HFF IC50
0.26 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
0.34 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
0.71 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
0.75 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
1 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
1.1 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
12.2 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
13.2 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
2.5 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
3.2 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
3.2 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
[PMID: 20145086]
HFF IC50
9.7 μM
Compound: 11
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
[PMID: 20145086]
体外研究
(In Vitro)

Pendimethalin (50 和 100 μM,24 小时) 显著降低人类血管内皮细胞 (HUVECs) 的细胞活力、导致细胞周期停滞、凋亡、内质网应激、自噬以及线粒体功能障碍[2]
Pendimethalin (25-100 μM,6 小时) 抑制 HUVECs 的迁移和管道形成[2]
Pendimethalin (50-200 μM,3 小时) 在人类淋巴细胞中表现出 DNA 损伤[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: HUVECs
Concentration: 50 and 100 μM
Incubation Time: 24 h
Result: Decreased the cell viability of 57% and 73% at 50 and 100 μM in HUVECs.

Cell Cycle Analysis[2]

Cell Line: HUVECs
Concentration: 50 and 100 μM
Incubation Time: 24 h
Result: Increased the proportion of cells in the G1 phase in HUVECs.

Apoptosis Analysis[2]

Cell Line: HUVECs
Concentration: 50 and 100 μM
Incubation Time: 24 h
Result: Significantly increased proportions of necrotic cells in HUVECs.
体内研究
(In Vivo)

Pendimethalin (12.5-50 mg/kg,口服强饲,每天一次,持续 14 天) 在大鼠骨髓细胞中表现出 DNA 损伤,并降低了 GSH 和 CAT 的水平,同时增加了 LPO 的水平[3]
Pendimethalin (62.5-250 mg/kg,口服一次,持续 14 天) 在大鼠的肝脏和肾脏中引起氧化应激,这表现在超氧化物歧化酶 (SOD)、过氧化氢酶 (CAT)、谷胱甘肽 (GSH) 和谷胱甘肽 S-转移酶 (GST) 水平明显下降,同时 TBARS 和羰基含量升高,导致肝脏和肾脏损伤,表现出库普弗细胞活化和白细胞浸润,以及细胞质大内泡化和血窦扩张[4]
Pendimethalin (62.5-250 mg/kg,口服一次,持续 14 天) 明显上调了抗炎和凋亡标志物,如肿瘤坏死因子 α (TNF-α)、干扰素 γ (IFN-γ)、Bax 和半胱氨酸蛋白酶-3 的表达,并下调了 Bcl-2,同时 TNF-α 基因的 mRNA 表达显著上调[4]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (140±10 g), 8–9 weeks[2]
Dosage: 12.5-50 mg/kg
Administration: oral gavage, daily for 14 days
Result: Induced 1.6, 4.9, and 10.5-fold (p<0.05) increase in comet OTM value at 12.5, 25, and 50 mg/kg b w/day.
分子量

281.31

Formula

C13H19N3O4

CAS 号
性状

固体

颜色

Orange to red

中文名称

二甲戊灵;二甲戊乐灵

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 50 mg/mL (177.74 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.5548 mL 17.7740 mL 35.5480 mL
5 mM 0.7110 mL 3.5548 mL 7.1096 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (8.89 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (8.89 mM); 悬浊液; 超声助溶

    此方案可获得 2.5 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。
您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.75%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.5548 mL 17.7740 mL 35.5480 mL 88.8699 mL
5 mM 0.7110 mL 3.5548 mL 7.1096 mL 17.7740 mL
10 mM 0.3555 mL 1.7774 mL 3.5548 mL 8.8870 mL
15 mM 0.2370 mL 1.1849 mL 2.3699 mL 5.9247 mL
20 mM 0.1777 mL 0.8887 mL 1.7774 mL 4.4435 mL
25 mM 0.1422 mL 0.7110 mL 1.4219 mL 3.5548 mL
30 mM 0.1185 mL 0.5925 mL 1.1849 mL 2.9623 mL
40 mM 0.0889 mL 0.4443 mL 0.8887 mL 2.2217 mL
50 mM 0.0711 mL 0.3555 mL 0.7110 mL 1.7774 mL
60 mM 0.0592 mL 0.2962 mL 0.5925 mL 1.4812 mL
80 mM 0.0444 mL 0.2222 mL 0.4443 mL 1.1109 mL
100 mM 0.0355 mL 0.1777 mL 0.3555 mL 0.8887 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Pendimethalin
目录号:
HY-B0862
需求量: